These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2992811)

  • 21. Detection and evaluation of feline oncornavirus-induced cell surface antigen(s) shed from cells in vitro.
    Wolff LH; Mathes LE; Schaller JP; Hoover EA; Olsen RG
    Cancer Res; 1977 Nov; 37(11):4134-7. PubMed ID: 198129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudotypes of feline sarcoma virus contain an 85,000-dalton protein with feline oncornavirus-associated cell membrane antigen (FOCMA) activity.
    Sherr CJ; Sen A; Todaro GJ; Sliski A; Essex M
    Proc Natl Acad Sci U S A; 1978 Mar; 75(3):1505-9. PubMed ID: 206902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective impairment of humoral immunity in feline leukemia virus-induced immunodeficiency.
    Pardi D; Hoover EA; Quackenbush SL; Mullins JI; Callahan GN
    Vet Immunol Immunopathol; 1991 Jul; 28(3-4):183-200. PubMed ID: 1659028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Feline leukemogenic and sarcomatogenic viruses].
    Parodi AL
    C R Seances Soc Biol Fil; 1975; 169(3 Suppl):794-806. PubMed ID: 175893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive immunotherapy of feline leukemia virus infection using autologous lymph node lymphocytes.
    Blakeslee J; Noll G; Olsen R; Triozzi PL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 May; 18(1):1-6. PubMed ID: 9593451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of normal lymphocyte mitogenic reactivity by serum from feline leukemia virus-infected cats.
    Cockerell GL; Hoover EA
    Cancer Res; 1977 Nov; 37(11):3985-9. PubMed ID: 198125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes.
    Flynn JN; Hanlon L; Jarrett O
    Immunology; 2000 Sep; 101(1):120-5. PubMed ID: 11012762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure and origins of the HZ2-feline sarcoma virus.
    Bergold PJ; Wang JY; Hardy WD; Littau V; Johnson E; Besmer P
    Virology; 1987 Jun; 158(2):320-9. PubMed ID: 2884777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro cytotoxicity and transplantation protection by autologous natural and activated killer cells against an in vitro transformed tumorigenic fibroblast line. A case study.
    Wilhelm SA; Mukherji B
    J Clin Invest; 1985 Apr; 75(4):1162-8. PubMed ID: 3988936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of complement-dependent lytic antibodies in sera from feline leukemia virus-infected cats by the chromium-51 release assay.
    Grant CK; Worley MB; DeBoer DJ
    J Natl Cancer Inst; 1977 Jan; 58(1):157-61. PubMed ID: 189040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active and passive immunization of cats with inactivated feline oncornaviruses.
    Schaller JP; Hoover EA; Olsen RG
    J Natl Cancer Inst; 1977 Nov; 59(5):1441-50. PubMed ID: 198563
    [No Abstract]   [Full Text] [Related]  

  • 32. Protection of cats against feline leukemia virus-positive and virus-negative tumors by complement-dependent antibody.
    Grant CK; Harris D; Essex ME; Pickard DK; Hardy WD; de Noronha F
    J Natl Cancer Inst; 1980 Jun; 64(6):1527-33. PubMed ID: 6246303
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanism of cell-mediated cytotoxicity at the single-cell level. VII. Trigger of the lethal hit event is distinct for NK/K and LDCC effector cells as measured in the two-target conjugate assay.
    Bradley TP; Bonavida B
    Cell Immunol; 1984 Jan; 83(1):199-207. PubMed ID: 6420079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of in vivo and in vitro interactions of feline immunodeficiency virus and feline leukemia virus.
    Beebe AM; Faith TG; Sparger EE; Torten M; Pedersen NC; Dandekar S
    AIDS; 1994 Jul; 8(7):873-8. PubMed ID: 7946095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility of human cell lines to feline leukemia virus and feline sarcoma virus.
    Azocar J; Essex M
    J Natl Cancer Inst; 1979 Nov; 63(5):1179-84. PubMed ID: 228103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
    Burns GF; Triglia T; Werkmeister JA
    J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three sizes of subunits in RNAs from feline sarcoma-leukaemia virus mixtures.
    Kimball PC; Rea TJ
    J Gen Virol; 1980 Dec; 51(Pt 2):295-305. PubMed ID: 6262439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ontogeny of natural killer cell activity and antibody dependent cell mediated cytotoxicity in pigs.
    Yang WC; Schultz RD
    Dev Comp Immunol; 1986; 10(3):405-18. PubMed ID: 3464523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of regional and distant lymph nodes in rejection of feline sarcoma virus-induced tumors in sheep.
    Thellen GH; Pedersen NC; Higgins J
    J Natl Cancer Inst; 1979 Aug; 63(2):389-400. PubMed ID: 222930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response to tumor cells in domestic animals.
    Trainin Z; Essex M
    J Am Vet Med Assoc; 1982 Nov; 181(10):1125-33. PubMed ID: 6294028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.